Barclays raised the firm’s price target on Solid Biosciences to $21 from $8 and keeps an Overweight rating on the shares. The analyst updated the company’s model to reflect progress made in SLB-003 program, recent financing from the private placement and the licensing agreement with Armatus Bio.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on SLDB:
- Solid Biosciences initiated with a Buy at Citi
- Piper upgrades Solid Biosciences to Overweight, still sees ‘significant upside’
- Solid Biosciences upgraded to Overweight from Neutral at Piper Sandler
- Solid Biosciences files $300M mixed securities shelf
- Solid Biosciences Provides Fourth Quarter and Full-Year 2023 Business Update and Financial Results
